Tilt training and pacing: a report on 9 patients with neurally mediated syncope

OBJECTIVE

In patients with neurally mediated syncope (NMS), pacing has been used to prevent bradycardia and syncope. However, recurrence due to the vasodepressor component remains a problem.

METHODS

We report on tilt training in 9 patients with a pacemaker (PM) implantation. Patients were submitted to daily in-hospital tilt testing. They were instructed to continue this therapy at home.

RESULTS

A negative tilt test was obtained in all patients. Six patients remained free from syncope. Recurrent syncope was observed in 3 patients. In 4 patients the pacemaker had been implanted before the start of the tilt training programme. Five patients had a pacemaker implanted after the administration of tilt training therapy.

CONCLUSION

NMS also occurs in paced patients.Tilt training improves the clinical outcome by restoring the vasoconstrictor reserve capacity.

Ultrastructural and Functional Remodeling of the Coupling Between Ca 2+ Influx and Sarcoplasmic Reticulum Ca 2+ Release in Right Atrial Myocytes From Experimental Persistent Atrial Fibrillation

Rationale : Persistent atrial fibrillation (AF) has been associated with structural and electric remodeling and reduced contractile function.

Objective : To unravel mechanisms underlying reduced sarcoplasmic reticulum (SR) Ca 2+ release in persistent AF.

Methods : We studied cell shortening, membrane currents, and [Ca 2+ ] i in right atrial myocytes isolated from sheep with persistent AF (duration 129±39 days, N=16), compared to matched control animals (N=21). T-tubule density, ryanodine receptor (RyR) distribution, and local [Ca 2+ ] i transients were examined in confocal imaging.

Results : Myocyte shortening and underlying [Ca 2+ ] i transients were profoundly reduced in AF (by 54.8% and 62%, P <0.01). This reduced cell shortening could be corrected by increasing [Ca 2+ ] i . SR Ca 2+ content was not different. Calculated fractional SR Ca 2+ release was reduced in AF (by 20.6%, P <0.05). Peak Ca 2+ current density was modestly decreased (by 23.9%, P <0.01). T-tubules were present in the control atrial myocytes at low density and strongly reduced in AF (by 45%, P <0.01), whereas the regular distribution of RyR was unchanged. Synchrony of SR Ca 2+ release in AF was significantly reduced with increased areas of delayed Ca 2+ release. Propagation between RyR was unaffected but Ca 2+ release at subsarcolemmal sites was reduced. Rate of Ca 2+ extrusion by Na + /Ca 2+ exchanger was increased.

Conclusions : In persistent AF, reduced SR Ca 2+ release despite preserved SR Ca 2+ content is a major factor in contractile dysfunction. Fewer Ca 2+ channel–RyR couplings and reduced efficiency of the coupling at subsarcolemmal sites, possibly related to increased Na + /Ca 2+ exchanger, underlie the reduction in Ca 2+ release.

Undersensing of ventricular fibrillation due to interference between a pacemaker and defibrillator in the same patient

Sensing in pacemakers (PMs) and implantable cardioverter defibrillators (ICDs) is crucial to normal device behaviour. Since both devices treat different arrhythmias, the technical approach to signal detection is also completely different. A PM has a fixed threshold of sensing, above which events are sensed and therapy of the device withheld. On the other hand, the defibrillator has a variable threshold of sensing to detect tachyarrhythmias, with sometimes very small and changing electrogram amplitudes. In this case report, we describe interference between a PM and an ICD caused by these differences in the detection of cardiac events, leading to undersensing of ventricular fibrillation at defibrillation threshold testing.

Pacemaker-mediated tachycardia with varying cycle length: what is the mechanism?

As new algorithms are being developed to promote intrinsic atrioventricular conduction in preventing the deleterious effects of right ventricular pacing, more complex rhythm strips can be encountered. In our patient with a dual-chamber implantable cardioverter-defibrillator, such an algorithm resulted in a pacemaker-mediated tachycardia with several changes in cycle length.

Contralateral pneumothorax after endocardial dual-chamber pacemaker implantation resulting from atrial lead perforation

We describe the occurrence of a right-sided pneumothorax following a left-sided dual chamber pacemaker implantation, due to a perforation of the screw of the J-shaped active-fixation lead through the right atrial wall. A review of the literature regarding complications of different atrial lead types (passive vs. active and J-shape vs. straight) is provided. Current data suggest that passive-fixation leads could have an advantage, provided they can be positioned satisfactorily because of the lower risk of pericardial complications. If active-fixation leads are used, straight leads might be preferable above J-shaped leads because of the lower rate of perforation.

Genetic and phenotypic differences among Enterococcus faecalis clones from intestinal colonisation and invasive disease

This study investigated the differences among Enterococcus faecalis isolates from the intestinal compartment of healthy volunteers (n = 36), intensive care unit (ICU) patients (n = 29) and blood isolates (n = 31) from the same institution, in comparison with seven epidemic clones from other institutions. In general, isolates from colonised ICU patients and from bacteraemic patients showed higher rates of antimicrobial resistance than isolates from colonised healthy volunteers, particularly for erythromycin and aminoglycosides. The proportion of isolates/clone was 1.05 in the community, 2.63 in the ICU, and 1.47 among bacteraemic cases, suggesting low clonal variation in ICUs. Two clones, RENC1 and RENC2, were frequently found as intestinal colonisers of ICU patients, and RENC1 was also found to colonise healthy volunteers. These two clones were a cause of bacteraemia in the institution studied, and RENC2 was also detected in various other Spanish hospitals. Both RENC1 and RENC2 were esp+, bacteriocin producers, and were resistant to all antibiotics tested except vancomycin and ampicillin. RENC1 produced haemolysin whereas RENC2 produced protease. The ace, agg, cylA, esp and gelE genes were more common among colonising strains from ICU patients than among isolates from individuals in the community. In both colonised groups (ICUs and the community), 40-50% of isolates harbouring the gelE and cylA genes did not express the corresponding phenotypes. Thus, the study indicated that particular E. faecalis clones might be well-adapted to hospital environments, and that surveillance should be directed specifically towards rapid detection of these disseminating clones in order to prevent infections and clonal spread.

Potential role of remote monitoring for scheduled and unscheduled evaluations of patients with an implantable defibrillator

AIMS

Follow-up of implantable cardioverter defibrillator (ICD) patients, with regular in-office visits every 3-6 months, puts a significant burden on specialized electrophysiology clinics. New technology allows for remote monitoring of device function. We wanted to investigate its potential reliability and to which extent its use can reduce in-office visits.

METHODS AND RESULTS

We retrospectively analysed data from 1739 prospectively coded ICD visits in a random set of 169 patients (followed between 2 month and 10.4 year in an academic centre). We defined (i) whether the visit was planned or not, (ii) what were the reasons for unplanned visits, (iii) whether any relevant finding was made, (iv) whether a remote monitoring system with the ability or not to detect pacing threshold would have been able to capture the problem, and (v) what actions were taken. The standard follow-up scheme consisted of in-office visits 1 month after implantation and then every 6 months, unless approaching battery depletion. From the 1739 visits, 1530 were performed according to clinical schedule (88%) and in 1197 of those (78.2%), no relevant finding was made. In 0.52% (n = 8) early post-implant pacing threshold increases would not have been detected by remote monitoring without the ability to determine thresholds (although two patients showed a high impedance). Moreover, in 6% of the planned visits, reprogramming would require a consecutive in-office visit (4%) or hospitalization (2%). Only 175 visits (9.6% of all) were conducted prior to the planned follow-up date due to patient symptoms [another 42 (2.4%) were due to planned surgery or safety warnings]. The proportion of relevant findings during unscheduled visits was significantly higher than during scheduled visits (80.6 vs. 21.8%; P < 0.0001) and a higher proportion of those was arrhythmia- and/or device-related (85.1 vs. 55.3%, P < 0.0001). Reprogramming was required more often (33.1 vs. 4%; P < 0.0001) and hospitalization rate was higher (18.3 vs. 2%; P < 0.0001), so that 51.4% of unscheduled visits would require in-office evaluation. Overall, remote follow-up would correctly exclude device function abnormalities or arrhythmic problems in 1402 (82.2%), identify an arrhythmic problem in 262 (15.3%), correctly identify a device-related problem in 35 (2.1%), but potentially miss an isolated pacing problem in 6 (0.46%). Clinical evaluation would diagnose a relevant clinical problem in the absence of any device interrogation abnormality in 170 patients (10%).

CONCLUSION

ICD remote monitoring can potentially diagnose >99.5% of arrhythmia- or device-related problems if combined with clinical follow-up by the local general practitioner and/or referring cardiologist. It may provide a way to significantly reduce in-office follow-up visits that are a burden for both hospitals and patients.

Appropriate and inappropriate implantable cardioverter defibrillator interventions during secondary prevention

BACKGROUND

ICD therapy is established therapy for secondary prevention after aborted sudden death or ventricular tachycardia. Long-term data on the incidence of appropriate and inappropriate interventions are scarce.

METHODS AND RESULTS

We retrospectively studied 391 patients with an ICD for secondary prophylaxis: 247 (63%) with ischaemic heart disease (IHD) and 144 without IHD (37%). Fifty-four patients were free from left ventricular structural disease. Mean follow-up was 30.8 months. Kaplan-Meier methodology was used for survival analysis. The use of beta-blockers was high and similar in both groups (85% IHD; 88% non-IHD; P = 0.36). The incidence of appropriate interventions was identical in IHD and non-IHD (42.7% and 47.8% at 4 y; HR 1.0, P = 0.99). There was a yearly rate of first intervention around 5% even in the fourth and fifth year after implantation. The incidence of inappropriate interventions was about half that of appropriate ICD interventions (21.4% at 4 y). It was higher in patients who also had received appropriate therapy (HR: 2.73 in the IHD group, 1.61 in the non-IHD group, P < 0.001 for both). Atrial fibrillation was the most common cause of inappropriate interventions in IHD, and sinus tachycardia in those without LV disease. The incidence of inappropriate interventions was not dependent on the type of ICD (VVI vs. DDD), in any group.

CONCLUSIONS

Patients with an ICD for secondary prophylaxis have a high rate of appropriate interventions, and remain at risk for developing a first intervention several years after implantation. Inappropriate interventions constitute a significant burden. Taking preventive measures (AV nodal slowing drugs, device selection and programming, patient counseling regarding allowable physical activity) is required to optimize the quality-of-life adjusted life-saving potential of ICDs.

REM sleep-related brady-arrhythmia syndrome

Rapid eye movement (REM) sleep-related brady-arrhythmia syndrome is a cardiac rhythm disorder characterised by asystoles lasting several seconds during REM sleep in otherwise healthy individuals. In contrast to arrhythmias associated with obstructive sleep apnea, REM sleep-related sinus arrests and atrioventricular (AV) blocks are not associated with episodes of apnea or hypopnea. In literature, only few cases have been published, suggesting that the prevalence of this nighttime rhythm disorder is very rare. In this paper, we report two new cases of REM sleep-related sinus arrests and one case of REM sleep-related total AV block. To explore the underlying mechanism, an analysis of heart rate variability was performed. In a matched control population, we observed a significant lower low-to-high frequency (LF/HF) ratio in slow wave sleep as compared to REM sleep (2.04 +/- 1.2 vs 4.55 +/- 1.82, respectively [Mann-Whitney U test p < 0.01]), demonstrating a global increase in sympathetic activity during REM. When using the same technique in two of three patients with REM-related arrhythmias, the shift to an increased LF/HF ratio from slow wave sleep to REM sleep tended to be lower. This may reflect an increased vagal activity (HF component) during REM sleep in these subjects. We, therefore, hypothesise that, in our patients with REM sleep-related arrhythmias, the overall dominance of sympathetic activity during REM is present but to a lesser extent and temporarily switches into vagal dominance when the bursts of REMs occur. As it was still unclear whether these REM sleep-related asystoles needed to be paced, we compared our treatment and these of previously reported cases with the current American College of Cardiology/American Heart Association guidelines for implantation of cardiac pacemakers.

Think outside the heart! Case report of Lyme disease

We report an interesting case of a young drug addict admitted to the emergency department with a high degree A-V block. The diagnosis of Lyme carditis was made and there was a progressive regression of the A-V block under antibiotic therapy. However, by focusing on the cardiac manifestations and misled by the patient's drug abuse, concomitant neurological manifestations were picked up late in the hospitalization. Missing the diagnosis of Lyme-meningoencephalitis could have compromised the patient's long-term prognosis. Therefore we stress the importance to think outside the heart as cardiologists!

Self-terminating AF depends on electrical remodeling while persistent AF depends on additional structural changes in a rapid atrially paced sheep model

The development of atrial fibrillation (AF) is associated with electrical and structural remodeling. The aim of this study was to assess the contribution of electrical and structural remodeling to the development of AF in a rapid atrially paced ovine model with and without His bundle ablation and to determine the role of the angiotensin pathway and matrix metalloproteinases in this process. Thirty-five sheep were rapidly paced in the atrium and were randomized to undergo His bundle ablation (HBA) (21 sheep; HBA sheep) or not (14 sheep; non-HBA sheep). After HBA the ventricles were paced at 80 bpm. Both groups were subdivided to receive active treatment (quinapril+losartan) or placebo. Sheep were followed for 15 weeks. Inducible AF was defined as a rapid irregular atrial rhythm lasting >1 min. Inducible AF was considered to be persistent if during further follow-up no sinus rhythm (SR) was documented anymore. The inducibility of AF with atrial tachypacing was not different between the 4 groups. On the other hand, non-HBA sheep developed persistent AF significantly earlier than HBA sheep (p=0.028). They had elevated ventricular rates, diminished atrial MMP-2, increased TIMP-2 expression, and more extensive atrial fibrosis. Active treatment in these sheep significantly lowered AT-II (p=0.018), prevented atrial fibrogenesis (p<0.001) and slowed the development of persistent AF (p=0.049). Electrical remodeling is sufficient to induce AF, while structural changes are needed for persistent AF. Fibrosis development in our model is the result of an increased expression of AT-II in combination with changes in MMP expression. Inhibition of the angiotensin pathway suppresses atrial fibrosis and the development of persistent AF.

Obesity Is a Major Determinant of Radiation Dose in Patients Undergoing Pulmonary Vein Isolation for Atrial Fibrillation

OBJECTIVES

This study sought to evaluate the impact of obesity on patient radiation dose during atrial fibrillation (AF) ablation procedures under fluoroscopic guidance.

BACKGROUND

Obesity is a risk factor for AF and its recurrence after ablation. It increases patient radiation dose during fluoroscopic imaging, but this effect has not been quantified for AF ablation procedures.

METHODS

Effective radiation dose and lifetime attributable cancer risk were calculated from dose-area product (DAP) measurements in 85 patients undergoing AF ablation guided by biplane low-frequency pulsed fluoroscopy (3 frames/s). Three dose calculation methods were used (Monte Carlo simulation, dose conversion coefficients, and depth-profile dose curves).

RESULTS

Median DAP for all patients was 119.6 Gy x cm2 (range 13.9 to 446.3 Gy x cm2) for procedures with a median duration of 4 h and 83 +/- 26 min of fluoroscopy. Body mass index was a more important determinant of DAP than total fluoroscopy time (r = 0.74 vs. 0.37, p < 0.001), with mean DAP values per hour of fluoroscopy of 58 +/- 40 Gy x cm2, 110 +/- 43 Gy x cm2, and 184 +/- 79 Gy x cm2 in normal, overweight, and obese patients, respectively. The corresponding effective radiation doses for AF ablation procedures were 15.2 +/- 7.8 mSv, 26.7 +/- 11.6 mSv, and 39.0 +/- 15.2 mSv, respectively (Monte Carlo). Use of conversion coefficients resulted in higher effective dose estimates than other methods, particularly in obese patients. Mean attributable lifetime risk of all-cancer mortality was 0.060%, 0.100%, and 0.149%, depending on weight class.

CONCLUSIONS

Obese patients receive more than twice the effective radiation dose of normal-weight patients during AF ablation procedures. Obesity needs to be considered in the risk-benefit ratio of AF ablation and should prompt further measures to reduce radiation exposure.

Ecological replacement of Enterococcus faecalis by multiresistant clonal complex 17 Enterococcus faecium

The proportion of enterococcal infections caused by ampicillin-resistant Enterococcus faecium (AREfm) in a European hospital increased from 2% in 1994 to 32% in 2005, with prevalence rates of AREfm endemicity of up to 35% in at least six hospital wards. Diabetes mellitus, three or more admissions in the preceding year, and use of beta-lactams and fluoroquinolones, were all associated with AREfm colonisation. Of 217 AREfm isolates that were genotyped, 97% belonged to clonal complex 17 (CC17). This ecological change mimics events preceding the emergence of vancomycin-resistant E. faecium (VREF) in the USA and may presage the emergence of CC17 VREF in European hospitals.

Patients with an unexplained microsatellite instable tumour have a low risk of familial cancer

The cancer risk is unknown for those families in which a microsatellite instable tumour is neither explained by MLH1 promoter methylation nor by a germline mutation in a mismatch repair (MMR) gene. Such information is essential for genetic counselling. Families suspected of Lynch syndrome (n=614) were analysed for microsatellite instability, MLH1 promoter methylation and/or germline mutations in MLH1, MSH2, MSH6, and PMS2. Characteristics of the 76 families with a germline mutation (24 MLH1, 2 PMS2, 32 MSH2, and 18 MSH6) were compared with those of 18 families with an unexplained microsatellite instable tumour. The mean age at diagnosis of the index patients in both groups was comparable at 44 years. Immunohistochemistry confirmed the loss of an MMR protein. Together this suggests germline inactivation of a known gene. The Amsterdam II criteria were fulfilled in 50/75 families (66%) that carried a germline mutation in an MMR gene and in only 2/18 families (11%) with an unexplained microsatellite instable tumour (P<0.0001). Current diagnostic strategies can detect almost all highly penetrant MMR gene mutations. Patients with an as yet unexplained microsatellite instable tumour likely carry a different type of mutation that confers a lower risk of cancer for relatives.

Nonpharmacologic Treatment of Atrial Fibrillation in Elderly Persons

In recent years, new nonpharmacologic possibilities have emerged for the treatment of atrial fibrillation. The roles of surgery, radiofrequency catheter ablation, pacing, and atrial defibrillation in the treatment of atrial fibrillation are discussed. This text focuses on the interaction between different treatment modalities and the pathophysiologic mechanisms of atrial fibrillation and on the available data about the effectiveness in elderly persons.

Reduced right ventricular ejection fraction in endurance athletes presenting with ventricular arrhythmias: a quantitative angiographic assessment

AIMS

Spontaneous or inducible sustained ventricular arrhythmias (VA) in endurance athletes frequently originate from the right ventricle (RV), even in the absence of familial arrhythmogenic RV cardiomyopathy (ARVC). The goal of this study was to determine whether the RV arrhythmogenic predilection in these patients is associated with RV functional abnormalities.

METHODS AND RESULTS

Biplane RV angiography was performed in three groups: 22 endurance athletes with VA, 15 matched athletes without VA, and 10 non-athletes without VA. Four methods for quantitative RV angiographic analysis (area length, Boak, pyramid monoplane, and pyramid biplane) were used to calculate RV end-diastolic volume (EDV) and end-systolic volume (ESV) (both corrected for body surface area) and ejection fraction (EF). In addition RV outflow tract shortening fraction (SF) was determined. Although only 6 of 22 (27%) athletes with VA fulfilled the diagnostic criteria for ARVC, RV arrhythmogenic involvement was manifest or probable in 82%, based on a combination of electrophysiologic, electrocardiographic, and morphologic criteria. RV EDV in athletes was higher than in non-athletes (area length: 100.3 +/- 26.9 vs. 69.6 +/- 14.3 mL/m(2), P = 0.001), without significant difference between athletes with and without VA. RV ESV, in contrast, was significantly higher in athletes with VA than in athletes without VA (52.6 +/- 22.3 vs. 35.5 +/- 11.2 mL/m(2), P = 0.004), resulting in a significantly lower RV EF, a consistent finding across all methods (area length: 49.1 +/- 10.4 vs. 63.7 +/- 6.4%, P < 0.001). This functional impairment was also reflected in a lower RV outflow tract SF (SF right anterior oblique 32.2 +/- 10.1 vs. 40.0 +/- 11.6%, P = 0.09; SF left anterior oblique (LAO) 31.9 +/- 7.8 vs. 39.0 +/- 10.5%, P = 0.10).

CONCLUSION

VA in high-level endurance athletes frequently originate from a mildly dysfunctional RV. This raises the question whether endurance exercise not only acts as a trigger for these arrhythmias but also as promoter of the RV changes.

Epicardial pacing: a single-centre study on 321 leads in 138 patients

OBJECTIVE

This study presents the long-term outcome of 321 epicardial leads in 138 patients.

METHODS AND RESULTS

All leads were Medtronic CapsureEpi model 4965 steroid eluting leads. The 1-, 3-, and 5-year patient survival was 91%, 83% and 77%, respectively.Twenty-seven patients died. In 25/27 deaths a pacing-related death could be excluded. Strangulation of the heart by an abandoned epicardial lead was the cause of death in one child. One other patient died suddenly at the age of 3 years. Failures occurred in 57 of 321 epicardial leads (18%). For all 321 leads, the 1-, 3- and 5-year freedom from failure was 91%, 85% and 71%, respectively. The cumulative proportion of patients without any lead defect was 85% after I year, 76% after 3 years and 62% after 5 years. The percentage of patients without serious adverse events at 1, 3, and 5 years was 97%, 91%, 85%, respectively. Lead fracture was the cause of failure in 15 leads of 9 patients. An important increase in pacing threshold occurred in 35 leads of 30 patients. Other failures were: diaphragmatic stimulation, infection, excessive traction and strangulation. Eighteen failures were repaired by 11 surgical interventions in 9 patients.Thirty-nine defects were corrected non-invasively in 31 patients.

CONCLUSIONS

The use of steroid-eluting epicardial leads has proven to be an adequate option. In paediatric cardiology, the epicardial approach remains an indispensable tool for achieving a life-long pacing.

Endurance sports is a risk factor for atrial fibrillation after ablation for atrial flutter

INTRODUCTION

Sports activity has been associated with the development of atrial arrhythmias. Atrial fibrillation (AF) is frequently observed after successful ablation for atrial flutter. Sports activity as a risk factor for AF development after flutter ablation has not been studied.

METHODS

We analyzed outcome in 137 patients (83% men) after ablation for isthmus-dependent atrial flutter (excluding patients with concomitant ablation for atrial tachycardia or fibrillation). Sports activity before and after ablation was evaluated by detailed questionnaires. Endurance sports was defined as (semi-)competitive participation in cycling, running or swimming for > or =3 h/week (and for > or =3 years pre-ablation). Median follow-up was 2.5 years. Survival free of AF was evaluated with Kaplan-Meier curves and log-rank statistics. Multivariate analysis was based on Cox proportional hazard evaluation.

RESULTS

Acute ablation success was 99% and flutter recurrence 4.4%. Thirty-one patients (23%) had been regularly engaged in endurance sports before ablation and 19 (14%) continued regular sports activity afterwards. Those performing sports were slightly younger. A history of endurance sports was a significant risk factor for post-ablation AF (univariate HR 1.96 (1.19-3.22), p<0.01, and multivariate HR 1.81 (1.10-2.98), p=0.02). Also continuation of endurance sports activity after ablation showed a trend for increased risk to develop AF despite a relatively small sample size (n=19; multivariate HR 1.68 (0.92-3.06), p=0.08). Cox proportional hazard calculations revealed a 10% and 11% increased risk for AF development per weekly hour sport performed before and after ablation respectively (p<0.01 for both).

CONCLUSION

A history of endurance sports activity is associated with the development of AF after ablation of atrial flutter.

Long-term symptomatic benefit after radiofrequency catheter ablation for atrial flutter despite a high incidence of post-procedural atrial fibrillation

OBJECTIVE

A high proportion of patients develops atrial fibrillation (AF) after ablation for atrial flutter (AFL). Radiofrequency ablation for AFL therefore would only be useful if it leads to a better quality of life despite this high incidence of AF post-ablation.

METHODS

All patients who underwent AFL ablation in our centre before March 2002 (n=203) were contacted by letter a median of 2.3 years after their ablation. Sixty-eight percent answered the questionnaire polling the perceived benefits of the procedure. The results were stratified according to the presenting arrhythmia before the ablation: only AFL, predominantly AFL, predominantly AF or class Ic-III AFL.

RESULTS

Despite a 60% incidence of AF, 84% considered the procedure to be beneficial during the 1st year and 77% during the 2nd year post-ablation. Patients with predominantly AF before the procedure showed significantly less overall improvement than the 3 other groups (50% and 33% after I year and 2 years, p< 0.01) and a smaller reduction in palpitations (50% and 29% after I year and 2 years, p < 0.01). The benefit of an ablation was also significantly less in patients who developed AF post-ablation than in patients who were completely arrhythmia free (75% versus 98% 1st year, 58% versus 91% 2nd year; p 0.01); nevertheless 75% of these patients reported fewer palpitations and 56% tolerated symptoms better than before.

CONCLUSIONS

Despite a high incidence of AF after AFL ablation, the majority of patients considered the intervention beneficial. Only in patients with predominantly AF before ablation the procedure does not seem beneficial.

Repeated tilt testing in patients with tilt-positive neurally mediated syncope

In this study we have included 222 patients with apparent neurally mediated syncope and with a positive diagnostic tilt test. The mean age was 33.4+/-21.2 years (median 25.3): there were 107 men (median age 25.3) and 115 women (median age 22.6). The age difference between males and females was statistically significant (P = 0.002). The response to the diagnostic tilt test was: type 1 (mixed) in 74 patients; type 2A (cardioinhibitory and bradycardia) in 6; type 2B (cardioinhibitory and asystole) in 61; type 3 (vasodepressor) in 81. In all 222 patients the diagnostic tilt test was positive after 19+/-11 min (mean+/-SD), median time: 18 min. For the four types of syncope, the duration in minutes of the diagnostic tilt test was: type 1 (mixed) 19.5+/-11.4; type 2A (cardioinhibitory) 24.8+/-13.6; type 2B (cardioinhibitory and asystole) 14.7+/-10.2; type 3 (vasodepressor) 21.6+/-11.1. A significant difference was found between type 2B and type 3 responses (P = 0.002). Between males and females no significant differences in the duration of the diagnostic tilt test were found, neither for all responses, nor for the four subtypes. A type 2B (cardioinhibitory and asystole) response occurred in 61 patients. The duration of asystole was 12.8+/-10.6s (mean+/-SD; median 9, minimum 3, maximum 60). The head-up tilt test was repeated day after day: one session per day. The response became negative at the second session in 119 patients (54%); at session 3 in 47 (21%); at session 4 in 30 (13%); at session 5 in 15 (7%); at session 6 in 6 (3%); at session 7 in 2 (1%); at session 8 in 3 (1%). For all 222 patients the mean number of sessions in order to obtain a negative tilt test was 2.9 (SD 1.3; median 2). Only 25% of patients remained tilt-positive for three or more sessions. A negative tilt test was ultimately obtained in every patient. Follow-up data are available for 202/222 patients. The time span between the first and last tilt test was 11.1+/-10 months (median 8.8). Of these 202 patients, 163 remained free of any event (80.7%).

Controversies in pacing: Indications and programming

This article reviews controversies in cardiac pacing in four areas: methods to prevent unnecessary right ventricular pacing and optimal ventricular pacing sites in the bradycardia population, pacing for prevention of atrial fibrillation (AF), a novel pacing technique for the treatment of heart failure, and pacing for the treatment of sleep apnea. Frequent right ventricular pacing has been reported to increase the incidence of AF and congestive heart failure. However, many patients with pacemakers for bradycardia have intrinsic atrioventricular conduction most of the time. Optimal programming of pacemakers and new algorithms designed to reduce unnecessary ventricular pacing are discussed. Pacing algorithms for prevention of AF have generally been shown to be ineffective. Atrial antitachycardia pacing has been shown to reduce the burden of atrial tachyarrhythmias in selected patients. Cardiac contractility modulation has recently been reported to be a promising new approach to the treatment of heart failure. Some pacing techniques may be effective in the treatment of sleep apnea but larger, long-term clinical trials are required to demonstrate a significant clinical benefit.

Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation

BACKGROUND

Atrial fibrillation (AF) is associated with extracellular matrix remodeling involving atrial fibrosis and atrial dilatation. Angiotensin II mediated pathways and matrix metalloproteinases (MMPs) have been implicated in these processes. Our aim was to study atrial structural remodeling and the expression of the angiotensin receptor subtypes and MMPs and their inhibitors (TIMPs) in patients with mitral valve disease with and without AF.

METHODS AND RESULTS

Biopsies from right and left atrial appendages (RA and LA) were taken from patients undergoing CABG (n=9, all in sinus rhythm (SR)) or mitral valve surgery (MVS; n=19; 9 with permanent AF and 10 in SR). Patients with MVS and AF had significantly larger atria (versus MVS and SR: p=0.02; versus CABG: p<0.01). The MVS patients had significantly more fibrosis than the control CABG group. Fibrosis was increased in both the AF and SR MVS groups in the LA, but only in the MVS-AF group in the RA. These AF patients had significantly more tricuspid regurgitation than SR patients. MMP-1 was down-regulated in LA of MVS patients (p=0.02) independent of the underlying rhythm (SR or AF; p=0.95). In RA biopsies, MMP-1 was down-regulated only in the MVS and AF group. MMP-9 was down-regulated in the MVS patients compared to CABG both in the RA and LA, and without a difference between the SR and AF groups. Protein expression of AT-1, AT-2, MMP-2, TIMP-1, -2 and -4, TNF-alpha, and TNF-alpha-converting enzyme did not differ significantly between the 3 groups.

CONCLUSIONS

Concordant changes between MMP-expression and fibrosis during mitral valve disease, both in LA and RA, suggest involvement of MMPs in structural atrial remodeling. AF itself did not contribute to altered fibrosis or MMP-expression in the LA. The association between AF and RA changes may be precipitated by greater hemodynamic load due to tricuspid regurgitation in these patients.

Molecular analysis of human, porcine, and poultry Enterococcus faecium isolates and their erm(B) genes

Fifty-nine erm(B)-positive Enterococcus faecium strains isolated from pigs, broilers, and humans were typed using multilocus sequence typing (MLST), and the coding sequence of the erm(B) gene was determined. Identical erm(B) gene sequences were detected in genetically unrelated isolates. Furthermore, genetically indistinguishable strains were found to contain different erm(B) alleles. This may suggest that horizontal exchange of the erm(B) gene between animal and human E. faecium strains or the existence of a common reservoir of erm(B) genes might be more important than direct transmission of resistant strains.

Unnoticed spread of integron-carrying Enterobacteriaceae in intensive care units

BACKGROUND

Integrons are strongly associated with multidrug resistance in Enterobacteriaceae. Little is known about the natural history of integron-associated resistance in hospitals during nonoutbreak periods. The prevalence of integrons and the incidence of cross-transmission and horizontal gene transfer in Enterobacteriaceae with reduced susceptibility to cephalosporins (ERSC) were determined for 2 intensive care units (ICUs).

METHODS

Microbiological surveillance using rectal swab samples obtained 2 times per week and genotyping using amplified fragment-length polymorphism (AFLP) were used to determine colonization with and genetic relatedness of ERSC. IntI1 integrase polymerase chain reaction (PCR), conserved-segment PCR, restriction fragment-length polymorphism, and DNA sequencing were used to determine the prevalence and contents of integrons.

RESULTS

Of 457 patients, 121 patients were colonized with ERSC, and 174 isolates underwent AFLP and PCR. In 34 isolates obtained from 31 patients, 11 different integrons were identified; these integrons encoded resistance to streptomycin/spectinomycin, gentamicin/tobramycin/kanamycin, chloramphenicol, and trimethoprim. Integrons could be divided into 7 clusters of > or =2 isolates each. Compared with isolates that were negative for integrons, isolates that were positive for integrons were associated with resistance to piperacillin, cephalosporins, aminoglycosides, and quinolones. Acquisition rates of integron-carrying ERSC were 10 cases per 1000 patient-days in the first ICU and 8 cases per 1000 patient-days in the second ICU, with most cases (26 of 34) being acquired during the ICU stay. Nineteen episodes resulted from cross-transmission. In addition, 2 cases of interspecies transfer and 1 case of intraspecies transfer of integrons were recorded. Younger age was independently associated with acquisition of integron-carrying ERSC (hazard ratio, 0.953; 95% confidence interval, 0.926-0.987).

CONCLUSION

Surveillance, genotyping, and integron analysis identified previously unnoticed outbreaks of integron-carrying ERSC. Cross-transmission appeared to be the dominant route of transmission. Therefore, barrier precautions are necessary to prevent further spread.

Ventricular high-rate episodes in pacemaker diagnostics identify a high-risk subgroup of patients with tachy-brady syndrome

OBJECTIVES

The purpose of this study was to evaluate the frequency and clinical significance of ventricular high-rate (VHR) episodes (ventricular rate >162 bpm) in patients with symptomatic bradycardia and paroxysmal atrial fibrillation (AF).

BACKGROUND

Newer pacemakers have enhanced diagnostic features that permit detection and storage of detailed information about the frequency, duration, and time of onset of multiple episodes of AF, atrial tachycardia (AT), and ventricular tachycardia (VT). However, the prevalence and prognostic value of AF associated with rapid ventricular rates in the pacemaker population are unknown.

METHODS

We prospectively followed 125 patients who received a Medtronic AT 500/501 pacemaker for symptomatic bradycardia and paroxysmal AF.

RESULTS

AF recurred in 112 patients (90%) during 22 +/- 8 months of follow-up. A total of 1,324 VHR episodes occurred in 38 patients (30%). Episodes with available electrograms (n = 560) were reviewed and classified as AF (n = 279; 50%), AT (n = 266; 47%) or VT (n = 15; 3%). AF burden was higher in patients with VHR episodes (median 1.9 vs 0.2 hours/day; P < .001). After controlling for AT/AF burden and heart disease, VHR episodes were a significant independent predictor of hospitalization for cardiovascular symptoms (odds ratio 2.92, 95% confidence interval 1.33-6.38; P = .007). Heart rate control improved over time in the cohort, and the frequency of VHR episodes decreased during follow-up (P < .001).

CONCLUSIONS

VHR episodes documented in the pacemaker diagnostics identify a high-risk subgroup of patients with AF. Monitoring VHR episodes may be useful for identifying pacemaker patients with AF who require more vigilant monitoring, additional investigations, and/or additional interventions.

Atrial fibrillation after radiofrequency ablation of atrial flutter: preventive effect of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics

OBJECTIVES

To determine risk factors for the development of atrial fibrillation (AF) after atrial flutter (AFL) ablation; and to study the relation between AF development and periprocedural drug use.

METHODS

AFL ablation was performed in 196 patients. The relation between AF occurrence and clinical, echocardiographic, and procedural factors and periprocedural drug use was analysed retrospectively by a Cox proportional hazard method.

RESULTS

After a median follow up of 2.2 years, 114 patients (58%) developed at least one AF episode. Factors associated with AF development were the presence of preprocedural AF, a history of cardioversion, and the number of antiarrhythmic drugs used before the procedure. Use of angiotensin converting enzyme (ACE) inhibitors/angiotensin II receptor blockers and diuretics was significantly associated by univariate and multivariate analyses with less development of AF.

CONCLUSIONS

A high proportion of patients develop AF after AFL ablation. The incidence of AF is related to pre-ablation AF and its persistence. ACE inhibitors/angiotensin II receptor blockers and diuretics seem to protect against AF.

Ablation of Focally Induced Atrial Fibrillation:. Selective or Extensive?

INTRODUCTION

Focally induced atrial fibrillation (AF) often is due to ectopic activity in the pulmonary veins (PV). Although initial approaches were aimed at ablating only the ectopic foci, more extensive ablation approaches have evolved that isolate all PVs empirically and/or create circumferential ablation lines in the left atrium (LA). These techniques last longer and may be associated with more risks. We retrospectively evaluated the outcome and risks of ablation for focally induced AF in a single-center patient population.

METHODS AND RESULTS

We report on 47 patients (32 men and 15 women; age 47 +/- 10 years) in whom 52 ablations were performed. In 19 patients (22 sessions), ablation was directed at the site(s) of overt ectopic activity ("selective" group), whereas in 28 patients (30 sessions) without sufficient ectopy to determine the culprit PV a mean of 3.5 PVs were empirically targeted for bidirectional disconnection from the LA ("extensive" group). On a preprocedural Holter recording, the "selective" group had significantly more isolated atrial ectopy (3,276 +/- 2,933 vs 620 +/- 937 beats/24 hours) and runs of atrial tachycardia (330 +/- 202 vs 53 +/- 87 runs/24 hours) than the "extensive" group (P < 0.01 for both). Only 11% had persistent AF before ablation. Acute procedural success was 81% (elimination of all ectopy) and 83%, respectively (bidirectional and fully circumferential isolation of all targeted PVs). Procedure and fluoroscopy times were significantly shorter in the "selective" group. There were no major complications, but 7 minor complications and 2 acute PV stenoses > 50% in the 30 "extensive" procedures were observed. Mean follow-up was 8.4 +/- 8.5 months (median 6.9). Kaplan-Meier analysis, excluding recurrences during only the first month ("delayed cure"), showed AF recurrence in 45% after 6 months and in 55% after 1 year. Outcome was not dependent on ablation approach ("selective" or "extensive") nor was time to first AF (22 +/- 64 days and 30 +/- 69 days). AF recurrence tended to be higher in patients with larger LA (P = 0.08), underlying heart disease or hypertension (P = 0.08), and those "extensive" patients in whom not all 4 PVs were targeted (P = 0.07).

CONCLUSION

Trigger-directed ablation for focally induced AF is associated with a relatively high recurrence rate during follow-up. Apart from recurrence of the ectopic trigger, this may point to underlying structural changes in the atrial substrate not addressed by the ablation. Prospective evaluation of the risk-to-benefit profile of any technique (selective, extensive, including linear lines) is required.

Do Population Studies Confirm the Benefit of Oral Anticoagulation in Atrial Fibrillation Demonstrated in Clinical Trials?

Atrial fibrillation (AF) is associated with a significant morbidity and mortality, mainly due to an increased risk of thromboembolic stroke. Several large randomized trials have demonstrated the efficacy of oral anticoagulation to reduce this risk of ischemic events in patients with non-valvular AF. Despite the translation of these results into clear practice guidelines, oral anticoagulation remains underused. This reflects doubts about the real effectiveness of oral anticoagulation in daily practice. This paper gives an overview of the available evidence of the effectiveness of oral anticoagulation in population studies and tries to identify some remaining barriers in the prescription of oral anticoagulation in real life.

Total Atrioventricular Nodal Ablation Increases Atrial Fibrillation Burden in Patients with Paroxysmal Atrial Fibrillation Despite Continuation of Antiarrhythmic Drug Therapy

INTRODUCTION

Total atrioventricular nodal (TAVN) ablation and pacing is an accepted and safe treatment for patients with drug-refractory paroxysmal atrial fibrillation (AF). Many patients develop permanent AF within the first 6 months after TAVN ablation. This usually is ascribed to the cessation of antiarrhythmic drug therapy. We hypothesized that TAVN ablation itself creates an atrial substrate prone to AF.

METHODS AND RESULTS

Patients participating in the Atrial Pacing Periablation for Paroxysmal Atrial Fibrillation (PA3) study who remained on stable antiarrhythmic drug therapy throughout follow-up were included in this analysis. AF burden and the development of persistent AF in the preablation period were compared to two consecutive postablation periods. Echocardiographic changes also were evaluated. Twenty-two patients remained on stable drug therapy (9 men and 13 women, age 59 +/- 3 years). One patient developed persistent AF preablation compared to 10 postablation (P < 0.05). AF burden preablation was 3.0 +/- 1.2 hours/day and increased to 10.4 +/- 2.2 hours/day and 11.8 +/- 2.3 hours/day in the two postablation follow-up periods (P < 0.05). In patients with fractional shortening (FS) >30% prior to ablation, FS decreased significantly from 39.4% +/- 1.3% to 36.4%+/- 1.7% (P < 0.05). In contrast, in patients with a FS < or =30% prior to ablation, FS increased from 27% +/- 0.8% to 33.6 +/- 1.7% (P < 0.05).

CONCLUSION

TAVN ablation increases AF burden and facilitates the development of persistent AF in patients with paroxysmal AF despite the continuation of antiarrhythmic drugs. Loss of AV and/or interventricular synchrony may lead to altered cardiac hemodynamics resulting in atrial stretch and increasing AF burden.

Pericardial effusion and right-sided pneumothorax resulting from an atrial active-fixation lead

We report on a patient in whom an active-fixation pre-shaped atrial lead caused perforation of the right atrial wall, pericardium and pleura, resulting in pericardial effusion and right-sided pneumothorax. Chest X-ray did not demonstrate protrusion of the atrial lead outside the cardiac silhouette but computed tomography visualized the tip of the helix of the atrial screw-in electrode outside the contours of the right atrial appendage touching the right upper lobe of the lung. The lead was repositioned with resolution of pericardial effusion and pneumothorax. Due to their proximity to the right lung, high anterolaterally positioned atrial screw-in leads carry a small but definite risk for right-sided pneumothorax.

New indications for pacing

This article reviews developments in four areas: single- versus dual-chamber pacing, pacing for prevention of atrial fibrillation (AF), pacing for the treatment of neuromediated syncope, and pacing in patients with congestive heart failure. Large, randomized clinical trials comparing physiologic and ventricular pacing in different pacemaker populations have demonstrated that physiologic pacing does prevent AF but does not reduce cardiac mortality or stroke. The benefit for prevention of AF appears to be in patients with sinus node disease as the primary indication for pacing. Selective atrial pacing algorithms designed for the prevention of AF have not been shown to substantially reduce the overall burden of AF. Cardiac pacing has been shown to have a moderate benefit in the treatment of neuromediated syncope. Cardiac resynchronization therapy is emerging as a promising new treatment for heart failure. Long-term studies report that it improves quality of life and functional capacity, and reduces hospitalizations for heart failure. The impact of this therapy on mortality awaits the results of ongoing studies.